.png)
This year’s Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting 2016, held April 19 to 22 in San Francisco, will feature a wide array of sessions. To help you create a smart itinerary, Managed Healthcare Executive Editorial Advisor David Calabrese, vice president and chief pharmacy officer, OptumRx, has identified 10 must-attend sessions.
View our Events Calendar to plan ahead for more upcoming events.
 | |
 Nosta | Technology-supported medicine and its impact on specialty pharmacy Tuesday, April 19 Presented by John Nosta, president, NostaLab; and Mike A. Payne, chief commercial officer and head of medical affairs, Omada Health, Inc.
|
 | |
.png)
During this session, presenters will discuss how technology-supported medicine will impact specialty pharmacy in the next three years.
| |
 Tharaldson | Specialty pharmaceuticals in Wednesday, April 20 8:45 a.m. to 10:00 a.m. Presented by: Aimee Tharaldson, PharmD, |
During this session, Tharaldson will discuss how specialty medications are affecting managed care pharmacy. She will focus on new and emerging specialty medications and explore their likely role in therapy.
| |
 Carden | Federal and state legislative Wednesday, April 20 Presented by: Reginia Grayson Benjamin, BS, JD, |
During this session, presenters will provide updates on the federal and state legislative and regulatory actions of interest to pharmacists and others in managed care and specialty pharmacy.
| |
 Jhawar | Integrated, data-driven approaches Wednesday, April 20 12:45 p.m. to 2 p.m. Presented by: Sharon K. Jhawar, PharmD, MBA, CGP, |
During this session, presenters will share best practices in designing data-driven strategies. They will share experience in implementing a pharmacy quality network pay-for-performance program to help improve member outcomes.
| |
 Schafer | Update on safety and economic
Wednesday, April 20 12:45 p.m. to 2 p.m. Presented by Jeremy A. Schafer, PharmD, MBA, |
During this session, presenters will compare recent safety and economic data of biosimilars through case studies of select European countries and the early experience in the US. They will also provide an outlook for biosimilars in the United States.
| |
 | Oncology value tools - are we ready to
2:30 p.m. to 3:45 p.m. Presented by Jennifer T. Chang, PharmD, MPH, |
During this session, Chang will provide an overview of two tools released by ASCO and NCCN and how a managed care organization utilizes these tools in the formulary review process.
| |
 Avery | Perspectives in assessing the
Wednesday, April 20 2:30 p.m. to 3:45 p.m. Presented by Steven G. Avey, RPh, MS, FAMCP,
|
During this presentation, presenters will share three perspectives (payer, manufacturer, societal) on how emerging therapies should be valued.
| |
 Burgdorf | Strategic management of high-cost
2:30 p.m. to 3:45 p.m. Presented by James R. Burgdorf, PhD, |
During this session, presenters will share a new approach that shifts utilization away from high-cost generics that have lower-cost alternatives.
| |
 Lang | Update on the electronic prior
Thursday, April 21 Presented by James R. Lang, PharmD, MBA,
|
During this session, presenters will provide an overview of the prior authorization and electronic prior authorization landscapes. They will also share how the industry is addressing key barriers.
| |
 Dull | Today's Medicaid program: Friday, April 22 8 a.m. to 9:15 a.m. Presented by Matthew Dull, BS, |
During this presentation, presenters will provide the current landscape of Medicaid with an emphasis of recent trends such as statewide/universal preferred drug lists, prior authorizations, and 340B issues.